Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – ASIT Biotech

Executive interview – ASIT Biotech

ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase III is a grass pollen AIT with the advantages of a very short administration. ASIT’s AITs require only four treatment visits in 3 weeks to the allergist prior to the pollen season rather than visits for most of the year which are needed with other subcutaneous AITs, or over many years for sublingual AITs. CEO, Thierry Legon, discusses the advantages of ASIT’s technology, its strong patent position and the timing for its next Phase III study, and the potential for ASIT’s technology platform to generate AITs in other allergy indications.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free